4//SEC Filing
Nabulsi Azmi 4
Accession 0000950170-25-008353
CIK 0001783183other
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 4:21 PM ET
Size
6.8 KB
Accession
0000950170-25-008353
Insider Transaction Report
Form 4
Nabulsi Azmi
Chief Operating Officer
Transactions
- Sale
Common Stock
2025-01-21$6.59/sh−7,886$51,957→ 233,390 total
Holdings
- 3,578.93(indirect: By 401(k))
Common Stock
- 785,700(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6650. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.
Documents
Issuer
Phathom Pharmaceuticals, Inc.
CIK 0001783183
Entity typeother
Related Parties
1- filerCIK 0001791412
Filing Metadata
- Form type
- 4
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 4:21 PM ET
- Size
- 6.8 KB